Dual-time-point imaging and delayed-time-point fluorodeoxyglucose-PET/computed tomography imaging in various clinical settings

PET Clinics

Volumn 11, Issue 1, 2016, Pages 65-84

  Houshmand, Sina ^a   Salavati, Ali ^a,b   Segtnan, Eivind Antonsen ^c   Grupe, Peter ^c   Høilund Carlsen, Poul Flemming ^c   Alavi, Abass ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; Dual time point imaging; FDG PET CT; Glucose 6 phosphatase; Inflammation

Indexed keywords

FLUORODEOXYGLUCOSE; TUMOR NECROSIS FACTOR INHIBITOR; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AORTA ATHEROSCLEROSIS; AREA UNDER THE CURVE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BROWN ADIPOSE TISSUE; CANCER CELL; CANCER PROGNOSIS; CAROTID ATHEROSCLEROSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CROHN DISEASE; DELAYED TIME POINT IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; DRUG UPTAKE; DUAL TIME POINT IMAGING; HUMAN; IMAGING; INFECTION; INFLAMMATION; INTERSTITIAL PNEUMONIA; LUNG CANCER; LUNG NODULE; LUNG SARCOIDOSIS; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); METASTASIS POTENTIAL; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TIME; TREATMENT RESPONSE; TUMOR VOLUME; ATHEROSCLEROSIS; BREAST NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; LUNG DISEASES; LUNG NEOPLASMS; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TIME FACTOR;

ATHEROSCLEROSIS; BREAST NEOPLASMS; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84947612593     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2015.07.003     Document Type: Review

References (107)

1. S. Hess, B.A. Blomberg, H.J. Zhu, and et al. The pivotal role of FDG-PET/CT in modern medicine Acad Radiol 21 2 2014 232 249
2. G. Cheng, D.A. Torigian, H. Zhuang, and et al. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging 40 5 2013 779 787
3. R. Hustinx, R.J. Smith, F. Benard, and et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck Eur J Nucl Med 26 10 1999 1345 1348
4. H. Zhuang, M. Pourdehnad, E.S. Lambright, and et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes J Nucl Med 42 9 2001 1412 1417
5. A. Matthies, M. Hickeson, A. Cuchiara, and et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules J Nucl Med 43 7 2002 871 875
6. T. Higashi, T. Saga, Y. Nakamoto, and et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer J Nucl Med 43 2 2002 173 180
7. S. Basu, T.C. Kwee, S. Surti, and et al. Fundamentals of PET and PET/CT imaging Ann N Y Acad Sci 1228 2011 1 18
8. C.A. Nelson, J.Q. Wang, I. Leav, and et al. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models Nucl Med Biol 23 4 1996 533 541
9. S. Suzuki, T. Toyota, H. Suzuki, and et al. Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase Arch Biochem Biophys 235 2 1984 418 426
10. L.G. Strauss Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients Eur J Nucl Med 23 10 1996 1409 1415
11. G.J. Cook, M.N. Maisey, and I. Fogelman Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine Eur J Nucl Med 26 10 1999 1363 1378
12. H. Zhuang, P.S. Duarte, M. Pourdehand, and et al. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging Clin Nucl Med 25 4 2000 281 284
13. K. Alkhawaldeh, G. Bural, R. Kumar, and et al. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules Eur J Nucl Med Mol Imaging 35 2 2008 246 252
14. C.C. Chang, S.F. Cho, Y.W. Chen, and et al. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma Clin Nucl Med 37 8 2012 e189 e195
15. R.L. Barger Jr., and K.R. Nandalur Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis Acad Radiol 19 2 2012 153 158
16. G. Cheng, S.F. Cho, Y.W. Chen, and et al. Serial changes of FDG uptake and diagnosis of suspected lung malignancy: a lesion-based analysis Clin Nucl Med 39 2 2014 147 155
17. K. Kaneko, E. Sadashima, K. Irie, and et al. Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging Ann Nucl Med 27 4 2013 392 399
18. A.N. Khan, and H. Al-Jahdali Value of delayed 18F-FDG PET in the diagnosis of solitary pulmonary nodule J Thorac Dis 5 3 2013 373 374
19. Y. Xiu, C. Bhutani, T. Dhurairaj, and et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity Clin Nucl Med 32 2 2007 101 105
20. M.G. Caprio, A. Cangiano, M. Imbriaco, and et al. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions Radiol Med 115 2 2010 215 224
21. A.M. Garcia Vicente, A. Soriano Castrejón, M.Á. Cruz Mora, and et al. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer Rev Esp Med Nucl Imagen Mol 33 1 2014 1 5
22. A.M. Garcia Vicente, A. Soriano Castrejón, F. Relea Calatayud, and et al. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer Rev Esp Med Nucl Imagen Mol 31 6 2012 308 314
23. R. Kumar, V.A. Loving, A. Chauhan, and et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET J Nucl Med 46 11 2005 1819 1824
24. A. Mavi, M. Urhan, J.Q. Yu, and et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes J Nucl Med 47 9 2006 1440 1446
25. A.A. Zytoon, K. Murakami, M.R. El-Kholy, and et al. Dual time point FDG-PET/CT imaging. Potential tool for diagnosis of breast cancer Clin Radiol 63 11 2008 1213 1227
26. R. Abgral, P.Y. Le Roux, J. Rousset, and et al. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma Nucl Med Commun 34 6 2013 551 556
27. A. Lyshchik, T. Higashi, Y. Nakamoto, and et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer Eur J Nucl Med Mol Imaging 32 4 2005 389 397
28. B.A. Blomberg, S.R. Akers, B. Saboury, and et al. Delayed time-point 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation Nucl Med Commun 34 9 2013 860 867
29. B.A. Blomberg, A. Thomassen, R.A. Takx, and et al. Delayed (1)(8)F-fluorodeoxyglucose PET/CT imaging improves quantitation of atherosclerotic plaque inflammation: results from the CAMONA study J Nucl Cardiol 21 3 2014 588 597
30. A. Chirindel, M. Chaudhry, J.O. Blakeley, and et al. 18F-FDG PET/CT qualitative and quantitative evaluation in NF1 patients for detection of malignant transformation - comparison of early to delayed imaging with and without liver activity normalization J Nucl Med 56 3 2015 379 385
31. A. Salavati, B. Saboury, and A. Alavi Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT" J Nucl Med 55 2 2014 350 351
32. J.T. Whaley, A.T. Fernandes, R. Sackmann, and et al. Clinical utility of integrated positron emission tomography/computed tomography imaging in the clinical management and radiation treatment planning of locally advanced rectal cancer Pract Radiat Oncol 4 4 2014 226 232
33. S. Houshmand, A. Salavati, S. Basu, and et al. The role of dual and multiple time point imaging of FDG uptake in both normal and disease states Clin Transl Imaging 2 4 2014 281 293
34. S. Basu, H. Zaidi, M. Houseni, and et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states Semin Nucl Med 37 3 2007 223 239
35. S. Basu, and A. Alavi Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging 34 10 2007 1527 1529
36. G. Cheng, A. Alavi, E. Lim, and et al. Dynamic changes of FDG uptake and clearance in normal tissues Mol Imaging Biol 15 3 2013 345 352
37. G. Cheng, A. Alavi, N.J. Lee, and et al. Differential background clearance of fluorodeoxyglucose activity in normal tissues and its clinical significance PET Clinics 9 2 2014 209 216
38. G.G. Choi, Y. Han, B. Weston, and et al. Metabolic effects of pulmonary obstruction on myocardial functioning: a pilot study using multiple time-point 18F-FDG-PET imaging Nucl Med Commun 36 1 2015 78 83
39. S. Basu, J. Kung, M. Houseni, and et al. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions Q J Nucl Med Mol Imaging 53 1 2009 9 19
40. G.A. Higgins, T.W. Shields, and R.J. Keehn The solitary pulmonary nodule. Ten-year follow-up of Veterans Administration-Armed Forces Cooperative Study Arch Surg 110 5 1975 570 575
41. G.A. Lillington, and C.I. Caskey Evaluation and management of solitary and multiple pulmonary nodules Clin Chest Med 14 1 1993 111 119
42. E. Laffon, H. de Clermont, H. Begueret, and et al. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions Nucl Med Commun 30 6 2009 455 461
43. Y.Y. Lin, J.H. Chen, H.J. Ding, and et al. Potential value of dual-time-point (1)(8)F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: a systematic review and meta-analysis Nucl Med Commun 33 10 2012 1011 1018
44. L. Zhang, Y. Wang, J. Lei, and et al. Dual time point 18FDG-PET/CT versus single time point 18FDG-PET/CT for the differential diagnosis of pulmonary nodules: a meta-analysis Acta Radiol 54 7 2013 770 777
45. M.K. Gould, C.C. Maclean, W.G. Kuschner, and et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis JAMA 285 7 2001 914 924
46. H.H. Chen, B.F. Lee, W.C. Su, and et al. The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer Eur J Nucl Med Mol Imaging 40 10 2013 1478 1485
47. M. Houseni, W. Chamroonrat, J. Zhuang, and et al. Prognostic implication of dual-phase PET in adenocarcinoma of the lung J Nucl Med 51 4 2010 535 542
48. Y. Satoh, A. Nambu, H. Onishi, and et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy Eur J Radiol 81 11 2012 3530 3534
49. S.J. Kim, Y.K. Kim, I.J. Kim, and et al. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC) Radiother Oncol 98 1 2011 105 108
50. Y.K. Kim, K.S. Lee, B.T. Kim, and et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients Cancer 109 6 2007 1068 1077
51. G. Shen, S. Hu, H. Deng, and et al. Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis Acta Radiol 56 6 2014 681 687
52. D.W. Kim, W.H. Kim, and C.G. Kim Dual-time-point FDG PET/CT: is it useful for lymph node staging in patients with non-small-cell lung cancer? Nucl Med Mol Imaging 46 3 2012 196 200
53. R. Siegel, C. DeSantis, K. Virgo, and et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 4 2012 220 241
54. T.A. Heusner, L.S. Freudenberg, H. Kuehl, and et al. Whole-body PET/CT-mammography for staging breast cancer: initial results Br J Radiol 81 969 2008 743 748
55. T.A. Heusner, S. Kuemmel, L. Umutlu, and et al. Breast cancer staging in a single session: whole-body PET/CT mammography J Nucl Med 49 8 2008 1215 1222
56. W.H. Choi, I.R. Yoo, J.H. O, and et al. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients Br J Radiol 84 1003 2011 593 599
57. S. Hahn, J. Hecktor, F. Grabellus, and et al. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients Acta Radiol 53 5 2012 518 523
58. L.W. Matthiessen, H.H. Johannesen, K. Skougaard, and et al. Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy Radiol Oncol 47 4 2013 358 365
59. A.A. Zytoon, K. Murakami, M.R. El-Kholy, and et al. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT Eur J Radiol 70 3 2009 530 538
60. E.K. Choi, IeR. Yoo, S.H. Kim, and et al. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease Clin Nucl Med 38 3 2013 e106 e111
61. F. Crippa, A. Gerali, A. Alessi, and et al. FDG-PET for axillary lymph node staging in primary breast cancer Eur J Nucl Med Mol Imaging 31 Suppl 1 2004 S97 S102
62. P.M. Price, R.D. Badawi, S.R. Cherry, and et al. Ultra staging to unmask the prescribing of adjuvant therapy in cancer patients: the future opportunity to image micrometastases using total-body 18F-FDG PET scanning J Nucl Med 55 4 2014 696 697
63. Y. Umeda, Y. Demura, T. Ishizaki, and et al. Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia Eur J Nucl Med Mol Imaging 36 7 2009 1121 1130
64. G.W. Hunninghake, U. Costabel, M. Ando, and et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders Sarcoidosis Vasc Diffuse Lung Dis 16 2 1999 149 173
65. NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes Ann Intern Med 94 1 1981 73 94
66. Y. Umeda, Y. Demura, M. Morikawa, and et al. Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis Respirology 16 4 2011 713 720
67. M. Vorster, M.M. Sathekge, and J. Bomanji Advances in imaging of tuberculosis: the role of (1)(8)F-FDG PET and PET/CT Curr Opin Pulm Med 20 3 2014 287 293
68. C.-J. Chen, B.F. Lee, W.J. Yao, and et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5 AJR Am J Roentgenol 191 2 2008 475 479
69. M.M. Sathekge, A. Maes, H. Pottel, and et al. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area S Afr Med J 100 9 2010 598 601
70. I.J. Kim, J.S. Lee, S.J. Kim, and et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity Eur J Nucl Med Mol Imaging 35 4 2008 808 814
71. J.M. Chang, H.J. Lee, J.M. Goo, and et al. False positive and false negative FDG-PET scans in various thoracic diseases Korean J Radiol 7 1 2006 57 69
72. R.S. Brown, J.Y. Leung, S.J. Fisher, and et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 36 10 1995 1854 1861
73. S.M. Bakheet, and J. Powe Benign causes of 18-FDG uptake on whole body imaging Semin Nucl Med 28 4 1998 352 358
74. M. Sathekge, A. Maes, and C. Van de Wiele FDG-PET imaging in HIV infection and tuberculosis Semin Nucl Med 43 5 2013 349 366
75. A. Hofmeyr, W.F. Lau, and M.A. Slavin Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response Tuberculosis (Edinb) 87 5 2007 459 463
76. I.N. Park, J.S. Ryu, and T.S. Shim Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography Clin Nucl Med 33 1 2008 1 3
77. M. Sathekge, A. Maes, M. Kgomo, and et al. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis J Nucl Med 52 6 2011 880 885
78. S. Gholami, A. Salavati, S. Houshmand, and et al. Assessment of atherosclerosis in large vessel walls: a comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification J Nucl Cardiol 22 3 2015 468 479
79. J. Bucerius, V. Mani, C. Moncrieff, and et al. Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels Eur J Nucl Med Mol Imaging 41 2 2014 369 383
80. M. Yun, S. Jang, A. Cucchiara, and et al. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors Semin Nucl Med 32 1 2002 70 76
81. M. Yun, D. Yeh, L.I. Araujo, and et al. F-18 FDG uptake in the large arteries: a new observation Clin Nucl Med 26 4 2001 314 319
82. A.R. Hairil Rashmizal, A.R. Noraini, C. Rossetti, and et al. Brown fat uptake of 18F-FDG on dual time point PET/CT imaging Singapore Med J 51 2 2010 e37 e39
83. K. Alkhawaldeh, and A. Alavi Quantitative assessment of FDG uptake in brown fat using standardized uptake value and dual-time-point scanning Clin Nucl Med 33 10 2008 663 667
84. S. Basu, and A. Alavi Optimizing interventions for preventing uptake in the brown adipose tissue in FDG-PET Eur J Nucl Med Mol Imaging 35 8 2008 1421 1423
85. B. Saboury, A. Salavati, A. Brothers, and et al. FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity Eur J Nucl Med Mol Imaging 41 4 2014 605 614
86. B. Saboury, A. Salavati, S. Sanz-Viedma, and et al. Pre-treatment dual-time-point FDG-PET/CT imaging may predict response in patients with Crohn's disease J Nucl Med Meeting Abstracts 54 2-MeetingAbstracts 2013 587
87. F.J. Cloran, K.P. Banks, W.S. Song, and et al. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity Lung Cancer 68 1 2010 66 71
88. M. Li, N. Wu, Y. Liu, and et al. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: additional diagnostic value of CT attenuation and dual-time-point imaging Eur J Radiol 81 8 2012 1886 1890
89. Z. Zheng, Y. Pan, F. Guo, and et al. Multimodality FDG PET/CT appearance of pulmonary tuberculoma mimicking lung cancer and pathologic correlation in a tuberculosis-endemic country South Med J 104 6 2011 440 445
90. P.J. Kok, J.E. van Eerd, O.C. Boerman, and et al. Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection Cancer Biother Radiopharm 20 3 2005 310 315
91. T.J. Makinen, P. Lankinen, T. Pöyhönen, and et al. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus Eur J Nucl Med Mol Imaging 32 11 2005 1259 1268
92. R.F. Yen, K.C. Chen, J.M. Lee, and et al. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging 35 7 2008 1305 1315
93. T. Shinozaki, K. Utano, H. Fujii, and et al. Routine use of dual time F-FDG PET for staging of preoperative lung cancer: does it affect clinical management? Jpn J Radiol 32 8 2014 476 481
94. S. Lee, T. Park, S. Park, and et al. The clinical role of dual-time-point (18)F-FDG PET/CT in differential diagnosis of the thyroid incidentaloma Nucl Med Mol Imaging 48 2 2014 121 129
95. S.J. Kim, Y.K. Kim, I.J. Kim, and et al. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients Clin Nucl Med 36 6 2011 434 439
96. K. Macdonald, J. Searle, and I. Lyburn The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5 Clin Radiol 66 3 2011 244 250
97. J.W. Lee, S.K. Kim, S.M. Lee, and et al. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer Mol Imaging Biol 13 3 2011 565 572
98. H.J. Yoon, S.K. Kim, T.S. Kim, and et al. New application of dual point 18F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer Clin Nucl Med 38 1 2013 7 12
99. A. Toriihara, S. Nakamura, K. Kubota, and et al. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors? AJR Am J Roentgenol 201 3 2013 639 644
100. M. Nakayama, A. Okizaki, S. Ishitoya, and et al. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions Ann Nucl Med 27 2 2013 163 169
101. D.L. Costantini, R. Vali, J. Chan, and et al. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors AJR Am J Roentgenol 200 2 2013 408 413
102. W.Y. Shum, T.C. Hsieh, J.J. Yeh, and et al. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma Eur J Radiol 81 5 2012 1024 1028
103. T. Shinya, S. Fujii, S. Asakura, and et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma Ann Nucl Med 26 8 2012 616 621
104. K.K. Miyake, Y. Nakamoto, and K. Togashi Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning Ann Nucl Med 26 6 2012 492 500
105. J.H. Lee, W.A. Lee, S.G. Park, and et al. Relationship between dual-time point FDG PET and immunohistochemical parameters in preoperative colorectal cancer: preliminary study Nucl Med Mol Imaging 46 1 2012 48 56
106. E. Prieto, J.M. Martí-Climent, I. Domínguez-Prado, and et al. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation J Nucl Med 52 6 2011 865 872
107. S.J. Kim, B.H. Kim, Y.K. Jeon, and et al. Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules Ann Nucl Med 25 5 2011 347 353